p185(HER2) overexpression in human breast cancer using molecular and immunohistochemical methods

Cancer Investigation

Volumn 18, Issue 4, 2000, Pages 336-342

  Johnson, Richard C ^a   Ricci Jr , Andrew ^a   Cartun, Richard W ^a   Ackroyd, Rocky ^a   Tsongalis, Gregory J ^a  

^a HARTFORD HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DNA; DOXORUBICIN; PROTEIN; TRASTUZUMAB; EPIDERMAL GROWTH FACTOR RECEPTOR 2;

ARTICLE; BREAST CANCER; CONTROLLED STUDY; GENE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; POLYACRYLAMIDE GEL ELECTROPHORESIS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROGNOSIS; BIOSYNTHESIS; BREAST TUMOR; CELL CULTURE; CHEMISTRY; COMPARATIVE STUDY; DNA PROBE; FEMALE; GENE EXPRESSION; GENETICS; METABOLISM; PATHOLOGY; PROTO ONCOGENE; SENSITIVITY AND SPECIFICITY;

BREAST NEOPLASMS; DNA PROBES; DNA, NEOPLASM; FEMALE; GENE EXPRESSION; GENES, ERBB-2; HUMANS; IMMUNOHISTOCHEMISTRY; POLYMERASE CHAIN REACTION; PROGNOSIS; RECEPTOR, ERBB-2; SENSITIVITY AND SPECIFICITY; TUMOR CELLS, CULTURED;

EID: 0033625553     PISSN: 07357907     EISSN: None     Source Type: Journal    
DOI: 10.3109/07357900009012176     Document Type: Article

References (25)

1. Slamon DJ, Godolphin W, Jones LA, et al: Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 244:707-712, 1989.
2. Lönn U, Lönn S, Nilsson B, et al: Prognostic value of erb-B2 and myc amplification in breast cancer imprints. Cancer 75:2681-2687, 1995.
3. Schechter AL, Stern DH, Vaidyanathan L, et al: The neu oncogene: an erb-B-related gene encoding a 185,000-Mr tumour antigen. Nature 312:513-516, 1984.
4. Bacus SS, Zelnick CR, Plowman G. et al: Expression of the erbB-2 family of growth factor receptors and their ligands in breast cancers. Implication for tumor biology and clinical behavior. Am J Clin Pathol 102(Suppl 1):S13-S24, 1994.
5. Goldman R, Ben Levy R, Peles K, et al: Heterodimerization of the erbB-1 and erbB-2 receptors in human breast carcinoma cells: a mechanism for receptor transregulation. Biochemistry 29: 11024-11028, 1990.
6. Carraway KL III, Sliwkowski MX, Akita R, et al: The erbB3 gene product is a receptor for heregulin. J Biol Chem 269:14303-14306, 1994.
7. Plowman G, Green J, Culouscou J-M, et al: Heregulin induces tyrosine phosphorylation of HER4/p180erbB4. Nature 366:473-475, 1993.
8. Kallioniemi OP, Holli K, Visakorpi T, et al: Association of c-erbB-2 protein overexpression with high rate of cell proliferation, increased risk of visceral metastasis and poor long-term survival in breast cancer. Int J Cancer 49:650-655, 1991.
9. Slamon DJ, Clark GM, Wong SG, et al: Human breast cancer: correlation of relapse and survival with amplification of the HER2/neu oncogene. Science 235:177-181, 1987.
10. Molland JG, Barraclough BH, Gebski V, et al: Prognostic significance of c-erbB-2 oncogene in axillary node-negative breast cancer. Aust. NZ J Surg 66:64-70, 1996.
11. Press MF, Pike MC, Chazin VR, et al: Her-2/neu expression in node-negative breast cancer: direct tissue quantification by computerized image analysis and association of overexpression with increased risk of recurrent disease. Cancer Res 53:4960-4970, 1993.
12. Stancovski I, Hurwitz, E, Leitner D, et al: Mechanistic aspects of the opposing effects of monoclonal antibodies to the erbB-2 receptor on tumor growth. Proc Natl Acad Sci USA 88:8691-8695, 1991.
13. HER2 monoclonal antibodies. Cancer Immunol Immunother 37:255-263, 1993.
14. Carter P, Presta L, Gorman CM, et al: Humanization of an anti-p185HER2 antibody for human cancer therapy. Proc Natl Acad Sci USA 89:4285-4289, 1992.
15. Jennings BA, Hadfield JE, Worsley SD, et al: Differential PCR assay for the detection of c-erbB 2 amplification used in a prospective study of breast cancer. J Clin Pathol Mol Pathol 50:254-256, 1997.
16. Csokay B, Papp J, Besznyak I, et al: Oncogene patterns in breast and ovarian carcinomas. Eur J Surg Oncol 19(Suppl 1):593-599, 1993.
17. HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer. J Clin Oncol 14:737-744, 1996.
18. HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment. J Clin Oncol 16:2659-2671, 1998.
19. Baselga J, Norton L, Albanell J, et al: Recombinant humanized anti-HER2 antibody (Herceptin™) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts. Cancer Res 58:2825-2831, 1998.
20. McNeil C: Herceptin raises its sights beyond advanced breast cancer [news]. J Natl Cancer Inst 90:882-883, 1998.
21. Thor AD, Berry DA, Budman DR, et al: erbB-2, p53 and efficacy of adjuvant therapy in lymph node-positive breast cancer. J Natl Cancer Inst 90:1346-1360, 1998.
22. Paik S, Bryant J, Park C, et al: erbB-2 and response to doxorubicin in patients with axillary lymph node-positive, hormone receptor-negative breast cancer. J Natl Cancer Inst 90:1361-1370, 1998.
23. HER2 overexpression, and intratumor heterogeneity in human breast cancer. Cancer Res 55:5400-5407, 1995.
24. Kraus MH, Popescu NC, Amsbaugh SC, et al: Overexpression of EGF receptor related proto-oncogene c-erb-B2 in human mammary tumor cell lines is by different molecular mechanisms. EMBO J 6:605-610, 1987.
25. Frye RA, Benz CC, Liu E: Detection of amplified oncogenes by differential polymerase chain reaction. Oncogene 4:1153-1157, 1989.